{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T17:37:43Z","timestamp":1792172263928,"version":"4.4.0"},"reference-count":77,"publisher":"Zhejiang University Press","issue":"7","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J. Zhejiang Univ. Sci. B"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1631\/jzus.b2300392","type":"journal-article","created":{"date-parts":[[2024,7,11]],"date-time":"2024-07-11T08:02:00Z","timestamp":1720684920000},"page":"557-567","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Nano-Bacillus Calmette-Gu\u00e9rin immunotherapies for improved bladder cancer treatment","\u7eb3\u7c73\u5361\u4ecb\u82d7\u6539\u5584\u8180\u80f1\u764c\u7684\u514d\u75ab\u6cbb\u7597\u6548\u679c"],"prefix":"10.1631","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6795-8024","authenticated-orcid":false,"given":"Sheng","family":"Zeng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaoqiang","family":"Xing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5961-9180","authenticated-orcid":false,"given":"Yifei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-4653-2316","authenticated-orcid":false,"given":"Haifeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"635","published-online":{"date-parts":[[2024,7,11]]},"reference":[{"issue":"2","key":"754_CR1","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1158\/0008-5472.CAN-03-1518","volume":"64","author":"T Akazawa","year":"2004","unstructured":"Akazawa T, Masuda H, Saeki Y, et al., 2004. Adjuvant-mediated tumor regression and tumor-specific cytotoxic response are impaired in MyD88-deficient mice. Cancer Res, 64(2):757\u2013764. https:\/\/doi.org\/10.1158\/0008-5472.can-03-1518","journal-title":"Cancer Res"},{"issue":"2","key":"754_CR2","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.acuro.2020.08.003","volume":"45","author":"M \u00c1lvarez-Maestro","year":"2021","unstructured":"\u00c1lvarez-Maestro M, Guerrero-Ramos F, Rodr\u00edguez-Faba O, et al., 2021. Current treatments for BCG failure in non-muscle invasive bladder cancer (NMIBC). Actas Urol Esp, 45(2):93\u2013102. https:\/\/doi.org\/10.1016\/j.acuro.2020.08.003","journal-title":"Actas Urol Esp"},{"issue":"1","key":"754_CR3","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1128\/IAI.01290-06","volume":"75","author":"CS Andersen","year":"2007","unstructured":"Andersen CS, Dietrich J, Agger EM, et al., 2007. The combined CTA1-DD\/ISCOMs vector is an effective intranasal adjuvant for boosting prior Mycobacterium bovis BCG immunity to Mycobacterium tuberculosis. Infect Immun, 75(1):408\u2013416. https:\/\/doi.org\/10.1128\/iai.01290-06","journal-title":"Infect Immun"},{"issue":"7","key":"754_CR4","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1016\/S1567-5769(01)00055-8","volume":"1","author":"I Azuma","year":"2001","unstructured":"Azuma I, Seya T, 2001. Development of immunoadjuvants for immunotherapy of cancer. Int Immunopharmacol, 1(7):1249\u20131259. https:\/\/doi.org\/10.1016\/s1567-5769(01)00055-8","journal-title":"Int Immunopharmacol"},{"issue":"1","key":"754_CR5","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.eururo.2021.08.010","volume":"81","author":"M Babjuk","year":"2022","unstructured":"Babjuk M, Burger M, Capoun O, et al., 2022. European Association of Urology guidelines on non-muscle-invasive bladder cancer (Ta, T1, and carcinoma in situ). Eur Urol, 81(1):75\u201394. https:\/\/doi.org\/10.1016\/j.eururo.2021.08.010","journal-title":"Eur Urol"},{"issue":"4","key":"754_CR6","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1038\/sj.bjc.6602026","volume":"91","author":"RFM Bevers","year":"2004","unstructured":"Bevers RFM, Kurth KH, Schamhart DHJ, 2004. Role of urothelial cells in BCG immunotherapy for superficial bladder cancer. Br J Cancer, 91(4):607\u2013612. https:\/\/doi.org\/10.1038\/sj.bjc.6602026","journal-title":"Br J Cancer"},{"issue":"8","key":"754_CR7","doi-asserted-by":"publisher","first-page":"230","DOI":"10.5489\/cuaj.7487","volume":"15","author":"B Bhindi","year":"2021","unstructured":"Bhindi B, Kool R, Kulkarni GS, et al., 2021. Canadian Urological Association guideline on the management of non-muscle-invasive bladder cancer \u2013 Abridged version. Can Urol Assoc J, 15(8):230\u2013239. https:\/\/doi.org\/10.5489\/cuaj.7487","journal-title":"Can Urol Assoc J"},{"issue":"3","key":"754_CR8","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1097\/01.ju.0000073852.24341.4a","volume":"170","author":"A B\u00f6hle","year":"2003","unstructured":"B\u00f6hle A, Brandau S, 2003. Immune mechanisms in bacillus Calmette-Guerin immunotherapy for superficial bladder cancer. J Urol, 170(3):964\u2013969. https:\/\/doi.org\/10.1097\/01.ju.0000073852.24341.4a","journal-title":"J Urol"},{"issue":"6","key":"754_CR9","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.biopha.2007.05.004","volume":"61","author":"S Brandau","year":"2007","unstructured":"Brandau S, Suttmann H, 2007. Thirty years of BCG immunotherapy for non-muscle invasive bladder cancer: a success story with room for improvement. Biomed Pharmacother, 61(6):299\u2013305. https:\/\/doi.org\/10.1016\/j.biopha.2007.05.004","journal-title":"Biomed Pharmacother"},{"issue":"2","key":"754_CR10","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.eururo.2012.07.033","volume":"63","author":"M Burger","year":"2013","unstructured":"Burger M, Catto JWF, Dalbagni G, et al., 2013. Epidemiology and risk factors of urothelial bladder cancer. Eur Urol, 63(2):234\u2013241. https:\/\/doi.org\/10.1016\/j.eururo.2012.07.033","journal-title":"Eur Urol"},{"key":"754_CR11","doi-asserted-by":"publisher","first-page":"977","DOI":"10.3389\/fphar.2017.00977","volume":"8","author":"JH Buss","year":"2018","unstructured":"Buss JH, Begnini KR, Bender CB, et al., 2018. Nano-BCG: a promising delivery system for treatment of human bladder cancer. Front Pharmacol, 8:977. https:\/\/doi.org\/10.3389\/fphar.2017.00977","journal-title":"Front Pharmacol"},{"issue":"1","key":"754_CR12","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.bbrc.2018.12.097","volume":"509","author":"MJ Cho","year":"2019","unstructured":"Cho MJ, Kim MJ, Kim K, et al., 2019. The immunotherapeutic effects of recombinant Bacillus Calmette-Gu\u00e9rin resistant to antimicrobial peptides on bladder cancer cells. Biochem Biophys Res Commun, 509(1):167\u2013174. https:\/\/doi.org\/10.1016\/j.bbrc.2018.12.097","journal-title":"Biochem Biophys Res Commun"},{"issue":"4","key":"754_CR13","doi-asserted-by":"publisher","first-page":"964.e7","DOI":"10.1016\/j.urology.2014.12.028","volume":"85","author":"SY Choi","year":"2015","unstructured":"Choi SY, Kim SJ, Chi BH, et al., 2015. Modulating the internalization of bacille Calmette-Gu\u00e9rin by cathelicidin in bladder cancer cells. Urology, 85(4):964.e7\u2013964.e12. https:\/\/doi.org\/10.1016\/j.urology.2014.12.028","journal-title":"Urology"},{"issue":"5","key":"754_CR14","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1016\/j.juro.2016.12.090","volume":"197","author":"R Chou","year":"2017","unstructured":"Chou R, Selph S, Buckley DI, et al., 2017. Intravesical therapy for the treatment of nonmuscle invasive bladder cancer: a systematic review and meta-analysis. J Urol, 197(5):1189\u20131199. https:\/\/doi.org\/10.1016\/j.juro.2016.12.090","journal-title":"J Urol"},{"issue":"12","key":"754_CR15","doi-asserted-by":"publisher","first-page":"10156","DOI":"10.1166\/jnn.2015.11690","volume":"15","author":"N Erdo\u011far","year":"2015","unstructured":"Erdo\u011far N, Iskit AB, Ero\u011flu H, et al., 2015. Antitumor efficacy of bacillus Calmette-Guerin loaded cationic nanoparticles for intravesical immunotherapy of bladder tumor induced rat model. J Nanosci Nanotechnol, 15(12):10156\u201310164. https:\/\/doi.org\/10.1166\/jnn.2015.11690","journal-title":"J Nanosci Nanotechnol"},{"issue":"2","key":"754_CR16","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/S0022-5347(17)36052-4","volume":"149","author":"JD Fleischmann","year":"1993","unstructured":"Fleischmann JD, Park MC, Hassan MO, 1993. Fibronectin expression on surgical specimens correlated with the response to intravesical bacillus Calmette-Guerin therapy. J Urol, 149(2):268\u2013271. https:\/\/doi.org\/10.1016\/s0022-5347(17)36052-4","journal-title":"J Urol"},{"issue":"10","key":"754_CR17","doi-asserted-by":"publisher","first-page":"2192","DOI":"10.1002\/cncr.25747","volume":"117","author":"J Gadiot","year":"2011","unstructured":"Gadiot J, Hooijkaas AI, Kaiser ADM, et al., 2011. Overall survival and PD-L1 expression in metastasized malignant melanoma. Cancer, 117(10):2192\u20132201. https:\/\/doi.org\/10.1002\/cncr.25747","journal-title":"Cancer"},{"issue":"3","key":"754_CR18","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/s41573-018-0007-y","volume":"18","author":"J Galon","year":"2019","unstructured":"Galon J, Bruni D, 2019. Approaches to treat immune hot, altered and cold tumours with combination immunotherapies. Nat Rev Drug Discov, 18(3):197\u2013218. https:\/\/doi.org\/10.1038\/s41573-018-0007-y","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"754_CR19","doi-asserted-by":"publisher","first-page":"79","DOI":"10.2174\/0929867311302010009","volume":"20","author":"C Gong","year":"2013","unstructured":"Gong C, Qi T, Wei X, et al., 2013. Thermosensitive polymeric hydrogels as drug delivery systems. Curr Med Chem, 20(1):79\u201394. https:\/\/doi.org\/10.2174\/0929867311302010009","journal-title":"Curr Med Chem"},{"issue":"9","key":"754_CR20","doi-asserted-by":"publisher","first-page":"2472","DOI":"10.1172\/JCI24617","volume":"115","author":"L Grode","year":"2005","unstructured":"Grode L, Seiler P, Baumann S, et al., 2005. Increased vaccine efficacy against tuberculosis of recombinant Mycobacterium bovis bacille Calmette-Gu\u00e9rin mutants that secrete listeriolysin. J Clin Invest, 115(9):2472\u20132479. https:\/\/doi.org\/10.1172\/jci24617","journal-title":"J Clin Invest"},{"issue":"9","key":"754_CR21","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1016\/j.vaccine.2012.12.053","volume":"31","author":"L Grode","year":"2013","unstructured":"Grode L, Ganoza CA, Brohm C, et al., 2013. Safety and immunogenicity of the recombinant BCG vaccine VPM1002 in a phase 1 open-label randomized clinical trial. Vaccine, 31(9):1340\u20131348. https:\/\/doi.org\/10.1016\/j.vaccine.2012.12.053","journal-title":"Vaccine"},{"issue":"5","key":"754_CR22","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1111\/j.1464-410X.2008.08235.x","volume":"103","author":"A Joraku","year":"2009","unstructured":"Joraku A, Homhuan A, Kawai K, et al., 2009. Immunoprotection against murine bladder carcinoma by octaarginine-modified liposomes incorporating cell wall of Mycobacterium bovis bacillus Calmette-Gu\u00e9rin. BJU Int, 103(5):686\u2013693. https:\/\/doi.org\/10.1111\/j.1464-410X.2008.08235.x","journal-title":"BJU Int"},{"issue":"1","key":"754_CR23","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1111\/cas.12075","volume":"104","author":"K Kawai","year":"2013","unstructured":"Kawai K, Miyazaki J, Joraku A, et al., 2013. Bacillus Calmette-Guerin (BCG) immunotherapy for bladder cancer: current understanding and perspectives on engineered BCG vaccine. Cancer Sci, 104(1):22\u201327. https:\/\/doi.org\/10.1111\/cas.12075","journal-title":"Cancer Sci"},{"issue":"4","key":"754_CR24","doi-asserted-by":"publisher","first-page":"361","DOI":"10.4111\/icu.20200602","volume":"62","author":"HS Kim","year":"2021","unstructured":"Kim HS, Seo HK, 2021. Emerging treatments for bacillus Calmette-Gu\u00e9rin-unresponsive non-muscle-invasive bladder cancer. Investig Clin Urol, 62(4):361\u2013377. https:\/\/doi.org\/10.4111\/icu.20200602","journal-title":"Investig Clin Urol"},{"issue":"2","key":"754_CR25","doi-asserted-by":"publisher","first-page":"228","DOI":"10.4111\/icu.20210425","volume":"63","author":"JH Kim","year":"2022","unstructured":"Kim JH, Choi J, Kim M, et al., 2022. Immunotherapeutic effects of recombinant Bacillus Calmette-Gu\u00e9rin containing sic gene in ex vivo and in vivo bladder cancer models. Investig Clin Urol, 63(2):228\u2013237. https:\/\/doi.org\/10.4111\/icu.20210425","journal-title":"Investig Clin Urol"},{"issue":"2","key":"754_CR26","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1159\/000355628","volume":"6","author":"J Kleinnijenhuis","year":"2014","unstructured":"Kleinnijenhuis J, Quintin J, Preijers F, et al., 2014. Long-lasting effects of BCG vaccination on both heterologous Th1\/Th17 responses and innate trained immunity. J Innate Immun, 6(2):152\u2013158. https:\/\/doi.org\/10.1159\/000355628","journal-title":"J Innate Immun"},{"issue":"16","key":"754_CR27","doi-asserted-by":"publisher","first-page":"5797","DOI":"10.1128\/JB.00336-06","volume":"188","author":"M Kov\u00e1cs","year":"2006","unstructured":"Kov\u00e1cs M, Halfmann A, Fedtke I, et al., 2006. A functional dlt operon, encoding proteins required for incorporation of D-alanine in teichoic acids in gram-positive bacteria, confers resistance to cationic antimicrobial peptides in Streptococcus pneumoniae. J Bacteriol, 188(16):5797\u20135805. https:\/\/doi.org\/10.1128\/jb.00336-06","journal-title":"J Bacteriol"},{"issue":"5","key":"754_CR28","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1002\/eji.201344300","volume":"44","author":"R Lai","year":"2014","unstructured":"Lai R, Jeyanathan M, Shaler CR, et al., 2014. Restoration of innate immune activation accelerates Th1-cell priming and protection following pulmonary mycobacterial infection. Eur J Immunol, 44(5):1375\u20131386. https:\/\/doi.org\/10.1002\/eji.201344300","journal-title":"Eur J Immunol"},{"issue":"1","key":"754_CR29","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/S0022-5347(17)55282-9","volume":"124","author":"DL Lamm","year":"1980","unstructured":"Lamm DL, Thor DE, Harris SC, et al., 1980. Bacillus Calmette-Guerin immunotherapy of superficial bladder cancer. J Urol, 124(1):38\u201342. https:\/\/doi.org\/10.1016\/S0022-5347(17)55282-9","journal-title":"J Urol"},{"issue":"3","key":"754_CR30","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/S0022-5347(17)37316-0","volume":"147","author":"DL Lamm","year":"1992","unstructured":"Lamm DL, van der Meijden APM, Morales A, et al., 1992. Incidence and treatment of complications of bacillus Calmette-Guerin intravesical therapy in superficial bladder cancer. J Urol, 147(3):596\u2013600. https:\/\/doi.org\/10.1016\/s0022-5347(17)37316-0","journal-title":"J Urol"},{"issue":"2","key":"754_CR31","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1111\/apm.13011","volume":"128","author":"ES Larsen","year":"2020","unstructured":"Larsen ES, Joensen UN, Poulsen AM, et al., 2020. Bacillus Calmette-Gu\u00e9rin immunotherapy for bladder cancer: a review of immunological aspects, clinical effects and BCG infections. Apmis, 128(2):92\u2013103. https:\/\/doi.org\/10.1111\/apm.13011","journal-title":"Apmis"},{"issue":"6","key":"754_CR32","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1007\/s00280-003-0597-9","volume":"51","author":"T Leakakos","year":"2003","unstructured":"Leakakos T, Ji C, Lawson G, et al., 2003. Intravesical administration of doxorubicin to swine bladder using magnetically targeted carriers. Cancer Chemother Pharmacol, 51(6):445\u2013450. https:\/\/doi.org\/10.1007\/s00280-003-0597-9","journal-title":"Cancer Chemother Pharmacol"},{"issue":"2","key":"754_CR33","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1166\/jnn.2021.18658","volume":"21","author":"L Liu","year":"2021","unstructured":"Liu L, Shen TT, Liu HF, et al., 2021. Toxicity effects of anthracycline-converted herceptin and azo-functionalized Fe3O4 nanoparticles on the heart of patients with breast cancer based on echocardiography. J Nanosci Nanotechnol, 21(2):878\u2013885. https:\/\/doi.org\/10.1166\/jnn.2021.18658","journal-title":"J Nanosci Nanotechnol"},{"issue":"1","key":"754_CR34","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/S1043-4666(02)00490-8","volume":"21","author":"Y Luo","year":"2003","unstructured":"Luo Y, Chen XH, O\u2019Donnell MA, 2003. Role of Th1 and Th2 cytokines in BCG-induced IFN-\u03b3 production: cytokine promotion and simulation of BCG effect. Cytokine, 21(1):17\u201326. https:\/\/doi.org\/10.1016\/s1043-4666(02)00490-8","journal-title":"Cytokine"},{"issue":"1","key":"754_CR35","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1111\/j.1365-2249.2004.02522.x","volume":"137","author":"Y Luo","year":"2004","unstructured":"Luo Y, Yamada H, Chen X, et al., 2004. Recombinant Mycobacterium bovis bacillus Calmette-Gu\u00e9rin (BCG) expressing mouse IL-18 augments Th1 immunity and macrophage cytotoxicity. Clin Exp Immunol, 137(1):24\u201334. https:\/\/doi.org\/10.1111\/j.1365-2249.2004.02522.x","journal-title":"Clin Exp Immunol"},{"issue":"2","key":"754_CR36","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.chom.2016.01.010","volume":"19","author":"Z Ma","year":"2016","unstructured":"Ma Z, Damania B, 2016. The cGAS-STING defense pathway and its counteraction by viruses. Cell Host Microbe, 19(2):150\u2013158. https:\/\/doi.org\/10.1016\/j.chom.2016.01.010","journal-title":"Cell Host Microbe"},{"issue":"12","key":"754_CR37","doi-asserted-by":"publisher","first-page":"5762","DOI":"10.1021\/acs.molpharmaceut.8b00919","volume":"15","author":"H Masuda","year":"2018","unstructured":"Masuda H, Nakamura T, Noma Y, et al., 2018. Application of BCG-CWS as a systemic adjuvant by using nanoparticulation technology. Mol Pharm, 15(12):5762\u20135771. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.8b00919","journal-title":"Mol Pharm"},{"issue":"8","key":"754_CR38","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1016\/S1567-5769(01)00071-6","volume":"1","author":"M Matsumoto","year":"2001","unstructured":"Matsumoto M, Seya T, Kikkawa S, et al., 2001. Interferon gamma-producing ability in blood lymphocytes of patients with lung cancer through activation of the innate immune system by BCG cell wall skeleton. Int Immunopharmacol, 1(8):1559\u20131569. https:\/\/doi.org\/10.1016\/s1567-5769(01)00071-6","journal-title":"Int Immunopharmacol"},{"issue":"5","key":"754_CR39","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1099\/mic.0.045997-0","volume":"157","author":"SM McBride","year":"2011","unstructured":"McBride SM, Sonenshein AL, 2011. The dlt operon confers resistance to cationic antimicrobial peptides in Clostridium difficile. Microbiology (Reading), 157(5):1457\u20131465. https:\/\/doi.org\/10.1099\/mic.0.045997-0","journal-title":"Microbiology (Reading)"},{"issue":"41","key":"754_CR40","doi-asserted-by":"publisher","first-page":"71249","DOI":"10.18632\/oncotarget.19531","volume":"8","author":"RFV Medrano","year":"2017","unstructured":"Medrano RFV, Hunger A, Mendon\u00e7a SA, et al., 2017. Immunomodulatory and antitumor effects of type I interferons and their application in cancer therapy. Oncotarget, 8(41):71249\u201371284. https:\/\/doi.org\/10.18632\/oncotarget.19531","journal-title":"Oncotarget"},{"issue":"9","key":"754_CR41","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1111\/j.1464-410X.2010.10056.x","volume":"108","author":"J Miyazaki","year":"2011","unstructured":"Miyazaki J, Kawai K, Kojima T, et al., 2011a. The liposome-incorporating cell wall skeleton of Mycobacterium bovis bacillus Calmette-Gu\u00e9in can directly enhance the susceptibility of cancer cells to lymphokine-activated killer cells through up-regulation of natural-killer group 2, member D ligands. BJU Int, 108(9):1520\u20131526. https:\/\/doi.org\/10.1111\/j.1464-410X.2010.10056.x","journal-title":"BJU Int"},{"issue":"6","key":"754_CR42","first-page":"2065","volume":"31","author":"J Miyazaki","year":"2011","unstructured":"Miyazaki J, Nishiyama H, Yano I, et al., 2011b. The therapeutic effects of R8-liposome-BCG-CWS on BBN-induced rat urinary bladder carcinoma. Anticancer Res, 31(6):2065\u20132071.","journal-title":"Anticancer Res"},{"key":"754_CR43","first-page":"315","volume":"49","author":"A Morales","year":"1978","unstructured":"Morales A, 1978. Adjuvant immunotherapy in superficial bladder cancer. Natl Cancer Inst Monogr, 49:315\u2013319.","journal-title":"Natl Cancer Inst Monogr"},{"key":"754_CR44","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.jconrel.2013.12.027","volume":"176","author":"T Nakamura","year":"2014","unstructured":"Nakamura T, Fukiage M, Higuchi M, et al., 2014. Nanoparticulation of BCG-CWS for application to bladder cancer therapy. J Control Release, 176:44\u201353. https:\/\/doi.org\/10.1016\/j.jconrel.2013.12.027","journal-title":"J Control Release"},{"issue":"5","key":"754_CR45","doi-asserted-by":"publisher","first-page":"5346","DOI":"10.3934\/mbe.2019267","volume":"16","author":"O Nave","year":"2019","unstructured":"Nave O, Hareli S, Elbaz M, et al., 2019. BCG and IL-2 model for bladder cancer treatment with fast and slow dynamics based on SPVF method\u2014stability analysis. Math Biosci Eng, 16(5):5346\u20135379. https:\/\/doi.org\/10.3934\/mbe.2019267","journal-title":"Math Biosci Eng"},{"key":"754_CR46","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.3389\/fimmu.2017.01147","volume":"8","author":"NE Nieuwenhuizen","year":"2017","unstructured":"Nieuwenhuizen NE, Kulkarni PS, Shaligram U, et al., 2017. The recombinant Bacille Calmette-Gu\u00e9rin vaccine VPM1002: ready for clinical efficacy testing. Front Immunol, 8:1147. https:\/\/doi.org\/10.3389\/fimmu.2017.01147","journal-title":"Front Immunol"},{"key":"754_CR47","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.ijbiomac.2012.11.026","volume":"54","author":"R Niranjan","year":"2013","unstructured":"Niranjan R, Koushik C, Saravanan S, et al., 2013. A novel injectable temperature-sensitive zinc doped chitosan\/\u03b2-glycerophosphate hydrogel for bone tissue engineering. Int J Biol Macromol, 54:24\u201329. https:\/\/doi.org\/10.1016\/j.ijbiomac.2012.11.026","journal-title":"Int J Biol Macromol"},{"issue":"3","key":"754_CR48","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/BF00205355","volume":"14","author":"T Ochiai","year":"1983","unstructured":"Ochiai T, Sato H, Hayashi R, et al., 1983. Postoperative adjuvant immunotherapy of gastric cancer with BCG-cell wall skeleton. 3- to 6-year follow up of a randomized clinical trial. Cancer Immunol Immunother, 14(3):167\u2013171. https:\/\/doi.org\/10.1007\/bf00205355","journal-title":"Cancer Immunol Immunother"},{"issue":"4","key":"754_CR49","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/j.nano.2009.02.002","volume":"5","author":"J Park","year":"2009","unstructured":"Park J, Fong PM, Lu J, et al., 2009. PEGylated PLGA nanoparticles for the improved delivery of doxorubicin. Nanomedicine, 5(4):410\u2013418. https:\/\/doi.org\/10.1016\/j.nano.2009.02.002","journal-title":"Nanomedicine"},{"issue":"6","key":"754_CR50","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/S0302-2838(02)00173-2","volume":"41","author":"JJ Patard","year":"2002","unstructured":"Patard JJ, Rodriguez A, Leray E, et al., 2002. Intravesical bacillus Calmette-Guerin treatment improves patient survival in T1G3 bladder tumours. Eur Urol, 41(6):635\u2013642. https:\/\/doi.org\/10.1016\/s0302-2838(02)00173-2","journal-title":"Eur Urol"},{"issue":"3","key":"754_CR51","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.micinf.2011.10.006","volume":"14","author":"PY Perera","year":"2012","unstructured":"Perera PY, Lichy JH, Waldmann TA, et al., 2012. The role of interleukin-15 in inflammation and immune responses to infection: implications for its therapeutic use. Microbes Infect, 14(3):247\u2013261. https:\/\/doi.org\/10.1016\/j.micinf.2011.10.006","journal-title":"Microbes Infect"},{"issue":"17","key":"754_CR52","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1097\/MD.0000000000000119","volume":"93","author":"MA P\u00e9rez-Jacoiste As\u00edn","year":"2014","unstructured":"P\u00e9rez-Jacoiste As\u00edn MA, Fern\u00e1ndez-Ruiz M, L\u00f3pez-Medrano F, et al., 2014. Bacillus Calmette-Gu\u00e9rin (BCG) infection following intravesical BCG administration as adjunctive therapy for bladder cancer: incidence, risk factors, and outcome in a single-institution series and review of the literature. Medicine (Baltimore), 93(17):236\u2013254. https:\/\/doi.org\/10.1097\/md.0000000000000119","journal-title":"Medicine (Baltimore)"},{"issue":"3","key":"754_CR53","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/nrurol.2014.15","volume":"11","author":"G Redelman-Sidi","year":"2014","unstructured":"Redelman-Sidi G, Glickman MS, Bochner BH, 2014. The mechanism of action of BCG therapy for bladder cancer\u2014a current perspective. Nat Rev Urol, 11(3): 153\u2013162. https:\/\/doi.org\/10.1038\/nrurol.2014.15","journal-title":"Nat Rev Urol"},{"issue":"1","key":"754_CR54","doi-asserted-by":"publisher","first-page":"1748981","DOI":"10.1080\/2162402X.2020.1748981","volume":"9","author":"CA Rentsch","year":"2020","unstructured":"Rentsch CA, Bosshard P, Mayor G, et al., 2020. Results of the phase I open label clinical trial SAKK 06\/14 assessing safety of intravesical instillation of VPM1002BC, a recombinant mycobacterium Bacillus Calmette Gu\u00e9rin (BCG), in patients with non-muscle invasive bladder cancer and previous failure of conventional BCG therapy. Oncoimmunology, 9(1):1748981. https:\/\/doi.org\/10.1080\/2162402X.2020.1748981","journal-title":"Oncoimmunology"},{"issue":"3","key":"754_CR55","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1002\/jps.22328","volume":"100","author":"WP Shi","year":"2011","unstructured":"Shi WP, Ji YW, Zhang XG, et al., 2011. Characterization of pH- and thermosensitive hydrogel as a vehicle for controlled protein delivery. J Pharm Sci, 100(3):886\u2013895. https:\/\/doi.org\/10.1002\/jps.22328","journal-title":"J Pharm Sci"},{"issue":"1","key":"754_CR56","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21654","volume":"71","author":"RL Siegel","year":"2021","unstructured":"Siegel RL, Miller KD, Fuchs HE, et al., 2021. Cancer statistics, 2021. CA Cancer J Clin, 71(1):7\u201333. https:\/\/doi.org\/10.3322\/caac.21654","journal-title":"CA Cancer J Clin"},{"issue":"50","key":"754_CR57","doi-asserted-by":"publisher","first-page":"7321","DOI":"10.1016\/j.vaccine.2021.09.040","volume":"39","author":"AK Singh","year":"2021","unstructured":"Singh AK, Srikrishna G, Bivalacqua TJ, et al., 2021. Recombinant BCGs for tuberculosis and bladder cancer. Vaccine, 39(50):7321\u20137331. https:\/\/doi.org\/10.1016\/j.vaccine.2021.09.040","journal-title":"Vaccine"},{"issue":"5863","key":"754_CR58","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1126\/science.1154253","volume":"319","author":"F Szoka","year":"2008","unstructured":"Szoka F, 2008. The art of assembly. Science, 319(5863):578\u2013579. https:\/\/doi.org\/10.1126\/science.1154253","journal-title":"Science"},{"key":"754_CR59","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.intimp.2016.03.007","volume":"35","author":"A Takeuchi","year":"2016","unstructured":"Takeuchi A, Eto M, Tatsugami K, et al., 2016. Antitumor activity of recombinant Bacille Calmette-Gu\u00e9rin secreting interleukin-15-Ag85B fusion protein against bladder cancer. Int Immunopharmacol, 35:327\u2013331. https:\/\/doi.org\/10.1016\/j.intimp.2016.03.007","journal-title":"Int Immunopharmacol"},{"issue":"17","key":"754_CR60","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.2217\/fon-2020-0137","volume":"16","author":"SM Tham","year":"2020","unstructured":"Tham SM, Mahendran R, Chiong E, et al., 2020. Gmcsf and Ifn\u03b1 gene therapy improves the response to BCG immunotherapy in a murine model of bladder cancer. Future Oncol, 16(17):1179\u20131188. https:\/\/doi.org\/10.2217\/fon-2020-0137","journal-title":"Future Oncol"},{"issue":"2","key":"754_CR61","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1182\/blood.V95.2.610","volume":"95","author":"I Tinhofer","year":"2000","unstructured":"Tinhofer I, Marschitz I, Henn T, et al., 2000. Expression of functional interleukin-15 receptor and autocrine production of interleukin-15 as mechanisms of tumor propagation in multiple myeloma. Blood, 95(2):610\u2013618. https:\/\/doi.org\/10.1182\/blood.V95.2.610","journal-title":"Blood"},{"issue":"5","key":"754_CR62","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1023\/B:PHAM.0000026436.62869.9c","volume":"21","author":"P Tyagi","year":"2004","unstructured":"Tyagi P, Li ZH, Chancellor M, et al., 2004. Sustained intravesical drug delivery using thermosensitive hydrogel. Pharm Res, 21(5):832\u2013837. https:\/\/doi.org\/10.1023\/b:pham.0000026436.62869.9c","journal-title":"Pharm Res"},{"issue":"12","key":"754_CR63","doi-asserted-by":"publisher","first-page":"3373","DOI":"10.1002\/eji.200737488","volume":"37","author":"WA Verri","year":"2007","unstructured":"Verri WA, Cunha TM, Ferreira SH, et al., 2007. IL-15 mediates antigen-induced neutrophil migration by triggering IL-18 production. Eur J Immunol, 37(12):3373\u20133380. https:\/\/doi.org\/10.1002\/eji.200737488","journal-title":"Eur J Immunol"},{"issue":"3","key":"754_CR64","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1158\/2326-6066.CIR-15-0009","volume":"3","author":"TA Waldmann","year":"2015","unstructured":"Waldmann TA, 2015. The shared and contrasting roles of IL2 and IL15 in the life and death of normal and neoplastic lymphocytes: implications for cancer therapy. Cancer Immunol Res, 3(3):219\u2013227. https:\/\/doi.org\/10.1158\/2326-6066.Cir-15-0009","journal-title":"Cancer Immunol Res"},{"issue":"18","key":"754_CR65","doi-asserted-by":"publisher","first-page":"4787","DOI":"10.1182\/blood-2010-10-311456","volume":"117","author":"TA Waldmann","year":"2011","unstructured":"Waldmann TA, Lugli E, Roederer M, et al., 2011. Safety (toxicity), pharmacokinetics, immunogenicity, and impact on elements of the normal immune system of recombinant human IL-15 in rhesus macaques. Blood, 117(18):4787\u20134795. https:\/\/doi.org\/10.1182\/blood-2010-10-311456","journal-title":"Blood"},{"issue":"14","key":"754_CR66","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1080\/09205063.2013.789357","volume":"24","author":"WX Wang","year":"2013","unstructured":"Wang WX, Zhang P, Shan WG, et al., 2013. A novel chitosan-based thermosensitive hydrogel containing doxorubicin liposomes for topical cancer therapy. J Biomater Sci Polym Ed, 24(14):1649\u20131659. https:\/\/doi.org\/10.1080\/09205063.2013.789357","journal-title":"J Biomater Sci Polym Ed"},{"issue":"10","key":"754_CR67","doi-asserted-by":"publisher","first-page":"3165","DOI":"10.1021\/nn900649v","volume":"3","author":"X Wang","year":"2009","unstructured":"Wang X, Li J, Wang YQ, et al., 2009. HFT-T, a targeting nanoparticle, enhances specific delivery of paclitaxel to folate receptor-positive tumors. ACS Nano, 3(10):3165\u20133174. https:\/\/doi.org\/10.1021\/nn900649v","journal-title":"ACS Nano"},{"issue":"24","key":"754_CR68","doi-asserted-by":"publisher","first-page":"3408","DOI":"10.1016\/j.vaccine.2018.03.009","volume":"36","author":"O World Health","year":"2018","unstructured":"World Health Organization, 2018. BCG vaccine: WHO position paper, February 2018 \u2013 Recommendations. Vaccine, 36(24):3408\u20133410. https:\/\/doi.org\/10.1016\/j.vaccine.2018.03.009","journal-title":"Vaccine"},{"issue":"3","key":"754_CR69","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1002\/med.21649","volume":"40","author":"JJ Wu","year":"2020","unstructured":"Wu JJ, Zhao L, Hu HG, et al., 2020. Agonists and inhibitors of the STING pathway: potential agents for immunotherapy. Med Res Rev, 40(3):1117\u20131141. https:\/\/doi.org\/10.1002\/med.21649","journal-title":"Med Res Rev"},{"issue":"1","key":"754_CR70","doi-asserted-by":"publisher","first-page":"e52835","DOI":"10.1371\/journal.pone.0052835","volume":"8","author":"DJ Wurpel","year":"2013","unstructured":"Wurpel DJ, Beatson SA, Totsika M, et al., 2013. Chaperoneusher fimbriae of Escherichia coli. PLoS ONE, 8(1):e52835. https:\/\/doi.org\/10.1371\/journal.pone.0052835","journal-title":"PLoS ONE"},{"issue":"2","key":"754_CR71","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/S0022-5347(05)67417-4","volume":"164","author":"H Yamada","year":"2000","unstructured":"Yamada H, Matsumoto S, Matsumoto T, et al., 2000. Murine IL-2 secreting recombinant Bacillus Calmette-Guerin augments macrophage-mediated cytotoxicity against murine bladder cancer MBT-2. J Urol, 164(2):526\u2013531. https:\/\/doi.org\/10.1016\/S0022-5347(05)67417-4","journal-title":"J Urol"},{"issue":"3","key":"754_CR72","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1016\/S0022-5347(01)65154-1","volume":"157","author":"S Yamamoto","year":"1997","unstructured":"Yamamoto S, Tsukamoto T, Terai A, et al., 1997. Genetic evidence supporting the fecal-perineal-urethral hypothesis in cystitis caused by Escherichia coli. J Urol, 157(3):1127\u20131129. https:\/\/doi.org\/10.1016\/S0022-5347(01)65154-1","journal-title":"J Urol"},{"issue":"15","key":"754_CR73","doi-asserted-by":"publisher","first-page":"6192","DOI":"10.1158\/0008-5472.CAN-09-1114","volume":"69","author":"DA Zaharoff","year":"2009","unstructured":"Zaharoff DA, Hoffman BS, Hooper HB, et al., 2009. Intravesical immunotherapy of superficial bladder cancer with chitosan\/interleukin-12. Cancer Res, 69(15):6192\u20136199. https:\/\/doi.org\/10.1158\/0008-5472.Can-09-1114","journal-title":"Cancer Res"},{"issue":"38","key":"754_CR74","doi-asserted-by":"publisher","first-page":"10258","DOI":"10.1016\/j.biomaterials.2013.09.027","volume":"34","author":"D Zhang","year":"2013","unstructured":"Zhang D, Sun P, Li P, et al., 2013. A magnetic chitosan hydrogel for sustained and prolonged delivery of Bacillus Calmette-Gu\u00e9rin in the treatment of bladder cancer. Biomaterials, 34(38):10258\u201310266. https:\/\/doi.org\/10.1016\/j.biomaterials.2013.09.027","journal-title":"Biomaterials"},{"issue":"5","key":"754_CR75","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1038\/sj.clpt.6100400","volume":"83","author":"L Zhang","year":"2008","unstructured":"Zhang L, Gu FX, Chan JM, et al., 2008. Nanoparticles in medicine: therapeutic applications and developments. Clin Pharmacol Ther, 83(5):761\u2013769. https:\/\/doi.org\/10.1038\/sj.clpt.6100400","journal-title":"Clin Pharmacol Ther"},{"key":"754_CR76","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1038\/s41467-020-15030-4","volume":"11","author":"W Zhang","year":"2020","unstructured":"Zhang W, Xu L, Park HB, et al., 2020. Escherichia coli adhesion portion FimH functions as an adjuvant for cancer immunotherapy. Nat Commun, 11:1187. https:\/\/doi.org\/10.1038\/s41467-020-15030-4","journal-title":"Nat Commun"},{"issue":"3","key":"754_CR77","doi-asserted-by":"publisher","first-page":"e003939","DOI":"10.1136\/jitc-2021-003939","volume":"10","author":"Y Zhang","year":"2022","unstructured":"Zhang Y, Huo F, Cao Q, et al., 2022. FimH confers mannosetargeting ability to Bacillus Calmette-Guerin for improved immunotherapy in bladder cancer. J Immunother Cancer, 10(3):e003939. https:\/\/doi.org\/10.1136\/jitc-2021-003939","journal-title":"J Immunother Cancer"}],"container-title":["Journal of Zhejiang University-SCIENCE B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1631\/jzus.B2300392.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1631\/jzus.B2300392\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1631\/jzus.B2300392.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T04:01:51Z","timestamp":1721793711000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1631\/jzus.B2300392"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":77,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["754"],"URL":"https:\/\/doi.org\/10.1631\/jzus.b2300392","relation":{},"ISSN":["1673-1581","1862-1783"],"issn-type":[{"value":"1673-1581","type":"print"},{"value":"1862-1783","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"4 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Sheng ZENG, Shaoqiang XING, Yifei ZhANG, Haifeng WANG, and Qian LIU declare that they have no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethics guidelines"}},{"value":"This review does not contain any studies with human or animal subjects performed by any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethics guidelines"}}]}}